Nonalcoholic Steatohepatitis | sciencenewsnet.in

Breaking News

Future Parents More Likely to Get RSV Vaccine When Pregnant if Aware That RSV Can Be a Serious Illness in Infants

Transforming Agriculture and Medicine: The Impact of Gene-Based Breeding (GBB)

ADDMAN Secures Qualification Project for CuNi Submarine Fittings with the US Navy

It’s easier now to treat opioid addiction with medication — but use has changed little

Researchers Publish Final Results of Key Clinical Trial for Gene Therapy for Sickle Cell Disease

A new report from the American Lung Association shows nearly 40% of people across the U.S. are living in areas that are heavily polluted.

Five facilities at Argonne where climate solutions are front and center

For Immigrants to Canada, Risk of MS Increases with Proportion of Life Spent There

Use of Acid Reflux Drugs Linked to Higher Risk of Migraine

Sweet potato quality analysis is enhanced with hyperspectral imaging and AI

25 Apr, 2024

Potential drug treats fatty liver disease in animal models, brings hope for first human treatment

April 10, 2023 sarah JonasResearch Results

A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.

Novel Antisense Drug Shows Promise in Slowing Fatty Liver Disease

June 16, 2020 sarah JonasResearch Results

A first-in-class clinical trial suggests a novel treatment measurably slowed progression of non-alcoholic fatty liver disease to its more progressive and deadly form.

Too Much of a Good Thing May Lead to Too Much of a Liver As Well

February 24, 2020 sarah JonasResearch Results

UC San Diego researchers suggest that prolonged exposure to a pair of antioxidant proteins may contribute to enlargement of the liver and fatty liver diseases.